<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04853355</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00073697</org_study_id>
    <nct_id>NCT04853355</nct_id>
  </id_info>
  <brief_title>Non-Responsive Diabetic Macular Edema and Spironolactone</brief_title>
  <official_title>Non-Responsive Diabetic Macular Edema in Patients With Pachychoroid and Choroidal Hyperpermeability.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic patients with macular edema and choroidal hyperpermeability (as manifested as a&#xD;
      thick choroid on OCT (optical coherence tomography) and ICG hyperfluorescence on ICG)&#xD;
      unresponsive to anti-VEGF (vascular endothelial growth factor) and steroid injections will be&#xD;
      treated with spironolactone in addition to the continued treatment of anti-VEGF injections,&#xD;
      specifically aflibercept (Eylea).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, prospective study of 10 patients referred during the years 2018 to&#xD;
      2020 with the diagnosis of Diabetic Macular Edema. Each patient was noted to have&#xD;
      pachychoroid, choroidal hyperpermeability, and most important resistant to multiple anti-VEGF&#xD;
      and steroid intravitreal injections, and have moderate vision loss. In addition, despite the&#xD;
      fact that we use anti-VEGF medications, we do not know the levels of VEGF in the eye, nor do&#xD;
      we have an explanation for the inability to respond to these drugs. This study will determine&#xD;
      the degree of VEGF concentrations, response to anti-VEGF treatments, and determine biomarkers&#xD;
      of inflammation as a means for explaining the cause of treatment resistance. Subsequently,&#xD;
      another pathological process will be treated with spironolactone to see if the degree of&#xD;
      contribution of choroidal hyperpermeability to the exudative process.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, non-randomized, pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eyes with complete reabsorption of intraretinal fluid</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular Edema - Central Subgroup Thickening</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Macular Edema - Volume</measure>
    <time_frame>1 year</time_frame>
    <description>Macular volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision, best corrected, logMAR units</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extrafoveal exudation (nCST)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetic Maculopathy</condition>
  <arm_group>
    <arm_group_label>Spironolactone Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-responsive Diabetic Macular Edema will be treated with Spironolactone in addition to the regular course of monthly aflibercept (Eylea).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone 50 mg</intervention_name>
    <description>Add Spironolactone 50 mg to previous regimen</description>
    <arm_group_label>Spironolactone Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          1. Presence of persistent Diabetic cystoid macular edema despite course of anti-VEGF&#xD;
             injections and intraocular steroids. At the time of study baseline, the patients must&#xD;
             be on q4 week intravitreal anti-VEGF medications and have failed (poor response - less&#xD;
             than 50% decrease in macular central subfield thickness (CST) and volume) with&#xD;
             intravitreal steroids (triamcinolone acetonide or dexamethasone implant).&#xD;
&#xD;
          2. Evidence of pachychoroid (choroid greater than 300 microns on OCT - EDI) with&#xD;
             pachyvessels on OCT or OCTA. In addition, ICG (Indocyanine Green Angiogram) must show&#xD;
             evidence of hyperfluorescence.&#xD;
&#xD;
          3. Visual Acuity of 20/25 to 20/400 at screening and baseline visits using an&#xD;
             autorefractor or Early Treatment Diabetic Retinopathy Study (ETDRS).&#xD;
&#xD;
          4. IOP ≤ 25 mmHg - Patients that screen fail due to elevated IOP ˃25 mmHg may rescreen&#xD;
             once IOP is treated and within normal limits (≤25 mmHg).&#xD;
&#xD;
        Exclusion:&#xD;
&#xD;
          1. Exudative maculopathies due to myopic choroidal degeneration, histoplasmosis, trauma,&#xD;
             and specifically, the presence of angioid streaks.&#xD;
&#xD;
          2. Myocardial infarction or cerebrovascular accident within the last 6 weeks&#xD;
&#xD;
          3. Previous vitrectomy&#xD;
&#xD;
          4. Hypokalemia&#xD;
&#xD;
          5. Optic neuropathy&#xD;
&#xD;
          6. Traction maculopathies&#xD;
&#xD;
          7. Allergies to fluorescein and indocyanine, dilating agents, spironolactone,&#xD;
             triamcinolone or anti-VEGF medications&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark H Nelson, MD MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark H. Nelson, MD MBA</last_name>
    <phone>336-971-5341</phone>
    <email>mhnelson@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kim DY, Lee JY, Lee EK, Kim JY. COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina. 2020 Jun;40(6):1191-1199. doi: 10.1097/IAE.0000000000002507.</citation>
    <PMID>30897068</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spironolactone</keyword>
  <keyword>anti-VEGF injections</keyword>
  <keyword>aflibercept</keyword>
  <keyword>Eylea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Available upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>12 months after completion date</ipd_time_frame>
    <ipd_access_criteria>Contact Principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

